Form 4: Oncology Institute Director Richard Barasch Reports Indirect Share Distribution

Oncology Institute Director and 10% owner Richard A. Barasch reported a distribution of 287,756 common shares from an entity he controls to another entity in which he holds a beneficial interest.

Summary

• Richard A. Barasch, a Director and 10% owner of Oncology Institute, Inc. (TOI), reported a change in his indirect beneficial ownership.
• On July 24, 2025, RAB Ventures (DFP) LLC, an entity controlled by Mr. Barasch, distributed 287,756 shares of common stock to Boro Partners Fund 1.
• The transaction was a distribution at a price of $0 per share, indicating a transfer of ownership rather than a sale.
• Following this transaction, Mr. Barasch's indirect beneficial ownership stands at 2,635,881 shares, held indirectly by an LLC.
• Mr. Barasch is a 10% beneficial owner of Boro Partners Fund 1 but disclaims investment control over Boro and beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The filing reports a routine change in indirect beneficial ownership by a director, which is generally neutral for the company's operational or financial outlook. It is an internal restructuring of holdings rather than a market transaction.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of an insider's change in beneficial ownership and does not provide broader insights into industry trends or competitive landscape within the oncology sector. It reflects an internal restructuring of shareholdings by a director.

Related Party Transactions

• RAB Ventures (DFP) LLC, an entity controlled by the reporting person, distributed shares to Boro Partners Fund 1, in which the reporting person holds a 10% beneficial interest.

Stakeholder Impact

• Shareholders: The transaction represents a change in the indirect ownership structure of a significant shareholder and director, but does not directly impact the total outstanding shares or the company's operational performance. It clarifies the beneficial ownership structure.

Key Dates

Recommendation

This Form 4 filing reports a change in indirect beneficial ownership by a director, which is a routine disclosure and does not provide sufficient information to warrant a 'buy' or 'sell' recommendation. The transaction is an internal restructuring of holdings and does not reflect a direct market sale or purchase by the insider that would typically signal strong sentiment. Therefore, a 'hold' recommendation is appropriate as this filing alone does not alter the fundamental investment thesis for Oncology Institute, Inc.

Keywords

Oncology Institute, TOI, Richard Barasch, SEC Form 4, Beneficial Ownership, Share Distribution, Director Ownership, Insider Trading, Corporate Governance